Funding and expenditure

MMV receives funding and support from government agencies, private foundations, international organizations, corporate foundations and private individuals. These funds are used to finance MMV’s portfolio of research and development (R&D) projects to develop new, effective and affordable medicines for the treatment and prevention of malaria. They also support specific, targeted access and product management (APM) interventions to help ensure that vulnerable populations in malaria-endemic countries can access new malaria medicines.

2021 expenditure: 84% directly supported R&D and access activities

 2021 diversity of funding sources

More details are available in the Financial section of our Annual Report.